WP8: Identifiing New Drug Targets - GPCR Screening

For the GPCR screening market the attraction lies in its exceptional profit opportunities and its substantial growth potential as more than 70% of all new drugs have GPCRs as targets. For example, GPCR agonists or antagonists are used as therapies for asthma either by promoting airway smooth muscle relaxation or by inhibiting inflammation in the nasal mucosa and airways. Their actual relevance is also evidenced by this year’s Nobel Prize in Chemistry shared by Brian Kobilka who is collaborating with the KU-Nano partner.